Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - Deferred ChargesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInvestment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Abivax (ABVX) Operating Expenses: 2022-2025

Historic Operating Expenses for Abivax (ABVX) over the last 1 years, with Jun 2025 value amounting to -$53.9 million.

  • Abivax's Operating Expenses fell 22.14% to -$53.9 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$148.7 million, marking a year-over-year decrease of 58.29%. This contributed to the annual value of $198.2 million for FY2024, which is 39.52% up from last year.
  • Abivax's Operating Expenses amounted to -$53.9 million in Q2 2025, which was down 6.26% from -$50.7 million recorded in Q1 2025.
  • Over the past 5 years, Abivax's Operating Expenses peaked at -$56.93 during Q4 2022, and registered a low of -$53.9 million during Q2 2025.
  • In the last 3 years, Abivax's Operating Expenses had a median value of -$47.0 million in 2024 and averaged -$33.1 million.
  • Data for Abivax's Operating Expenses shows a maximum YoY tumbled of 137.38% (in 2023) over the last 5 years.
  • Over the past 4 years, Abivax's Operating Expenses (Quarterly) stood at -$56.93 in 2022, then crashed by 137.38% to -$135.14 in 2023, then tumbled by 41.86% to -$191.71 in 2024, then dropped by 22.14% to -$53.9 million in 2025.
  • Its Operating Expenses was -$53.9 million in Q2 2025, compared to -$50.7 million in Q1 2025 and -$191.71 in Q4 2024.